Vanguard Group Inc Gt Biopharma, Inc. Transaction History

Vanguard Group Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.22 - $0.28 $166 - $212	759 Added 0.07%	1,087,993 $282,000
Q3 2023 Nov 14, 2023	SELL	$0.24 - $0.35 $2,908 - $4,242	-12,120 Reduced 1.1%	1,087,234 $260,000
Q2 2023 Aug 14, 2023	SELL	$0.22 - $0.55 $6,171 - $15,428	-28,051 Reduced 2.49%	1,099,354 $340,000
Q4 2022 Feb 10, 2023	BUY	$0.89 - $58.2 $412 - $27,004	464 Added 0.04%	1,127,405 $1 Million
Q3 2022 Nov 14, 2022	BUY	$1.81 - $56.1 $181 - $5,610	100 Added 0.01%	1,126,941 $1.98 Million
Q2 2022 Aug 12, 2022	BUY	$1.64 - $3.11 $227,794 - $431,975	138,899 Added 14.06%	1,126,841 $3.37 Million
Q1 2022 May 13, 2022	SELL	$2.6 - $3.3 $567,866 - $720,753	-218,410 Reduced 18.1%	987,942 $2.85 Million
Q4 2021 Feb 14, 2022	BUY	$3.05 - $7.08 $741,238 - $1.72 Million	243,029 Added 25.23%	1,206,352 $3.68 Million
Q3 2021 Nov 12, 2021	SELL	$6.68 - $15.26 $126,559 - $289,115	-18,946 Reduced 1.93%	963,323 $6.49 Million
Q2 2021 Aug 13, 2021	BUY	$7.19 - $18.96 $7.06 Million - $18.6 Million	982,269 New	982,269 $15.2 Million

564

Ticker GTBP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,557,700
Market Cap $96.4M
Description
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate th...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.